Comparative analysis of acute and chronic administration of haloperidol and clozapine using [3H] 2-deoxyglucose metabolic mapping

Schizophrenia Research

Volumn 61, Issue 2-3, 2003, Pages 195-205

  Wotanis, Jill ^a   Hanak, Susan E ^a   Wettstein, Joseph G ^a   Black, Mark D ^a  

^a SANOFI   (France)

Author keywords

2 deoxyglucose; Antipsychotics; Metabolic mapping; Multivariate analysis; Schizophrenia

Indexed keywords

CLOZAPINE; DEOXYGLUCOSE; HALOPERIDOL; TRITIUM;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN METABOLISM; BRAIN REGION; CAUDATE NUCLEUS; CENTRAL GRAY MATTER; CEREBELLUM; CHRONIC DRUG ADMINISTRATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG MECHANISM; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HIPPOCAMPUS; LOCUS CERULEUS; MALE; MEASUREMENT; METABOLIC PARAMETERS; NONHUMAN; OPTICAL DENSITY; PRIORITY JOURNAL; PUTAMEN; RAT; SUPERIOR COLLICULUS; THALAMUS;

EID: 0037410571     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(02)00230-X     Document Type: Article

References (46)

1. Andreasen N.C. The role of the thalamus in schizophrenia. Can. J. Psychiatry. 42(1):1997;27-33.
2. Asper H., Baggiolini M., Burki H.R., Launer H., Ruch W., Stille G. Tolerance phenomena with neuroleptics. Catalepsy, apomorphine stereotypies and striatal dopamine metabolism in the rat after single and repeated administration of loxapine and haloperidol. Eur. J. Pharmacol. 22:1973;287-294.
3. Bartlett E.J., Brodie J.D., Simkowitz P., Dewey S.L., Rusinek H., Wolf A.P., Fowler J.S., Volkow N.D., Smith G., Wolkin A. Effects of haloperidol challenge on regional cerebral glucose utilization in normal human subjects. Am. J. Psychiatry. 151(5):1994;681-686.
4. 2 subtypes of dopamine receptors in rat brain. J. Neurosci. 6:1986;3177-3188.
5. Buchsbaum M.S., Someya T., Teng C.Y., Chin S., Najafi A., Haier R.J., Wu J., Bunney W.E. PET and MRI of the thalamus in never-medicated patients with schizophrenia. Am. J. Psychiatry. 153(2):1996;191-199.
6. Carlsson A., Waters N., Waters S., Carlsson M.L. Network interactions in schizophrenia - therapeutic implications. Brain Res. Rev. 31(2-3):2000;342-349.
7. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu. Rev. Pharmacol. Toxicol. 41:2001;237-260.
8. 2 receptors in the rat brain: autoradiographic visualization using a high-affinity selective agonist ligand. J. Neurosci. 7:1987;1352-1360.
9. Cohen R.M., Nordahl T.E., Semple W.E., Andreason P., Litman R.E., Pickar D. The brain metabolic patterns of clozapine- and fluphenazine-treated patients with schizophrenia during a continuous performance task. Arch. Gen. Psychiatry. 54(5):1997;481-486.
10. Colangelo V., DiGrezia R., Passarelli F., Musicco M., Pontieri F.E., Orzi F. Differential effects of acute administration of clozapine or haloperidol on local cerebral glucose utilization in the rat. Brain Res. 768:1997;273-278.
11. Danos P., Guich S., Abel L., Buchsbaum M.S. EEG alpha rhythm and glucose metabolic rate in the thalamus in schizophrenia. Neuropsychobiology. 43:2001;265-272.
12. Duncan G.E., Moy S.S., Knapp D.J., Mueller R.A., Breese G.R. Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia. Brain Res. 787:1998;181-190.
13. Duncan G.E., Leipzig J.N., Mailman R.B., Lieberman J.A. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res. 812:1998;65-75.
14. Duncan G.E., Miyamoto S., Leipzig J.N., Lieberman J.A. Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. Brain Res. 843:1999;171-183.
15. Ezrin-Waters C., Seeman P. Tolerance to haloperidol catalepsy. Eur. J. Pharmacol. 41:1977;321-327.
16. Frederick J.A., Meador-Woodruff J.H. Effects of clozapine and haloperidol on 5-HT6 receptor mRNA levels in rat brain. Schizophr. Res. 38(1):1999;7-12.
17. 3H] sulpiride. Neurochem. Int. 7:1985;717-723.
18. 2 dopamine antagonists. Neuropsychopharmacology. 14(3S):1996;35S-39S.
19. Huerta M.F., Harting J.K. Connectional organization of the superior colliculus. Trends Neurosci. 7(8):1984;286-289.
20. Janssen P.A., Niemegeers C.J., Jageneau A.H. Apomorphine antagonism in rats. Arzneim.-Forsch. 10:1960;1003.
21. Kim Y.B., Jang J., Chung Y., Baeg E.H., Kim H.T., Mook-Jung I., Kim S.U., Jung M.W., Chung Y.K. Haloperidol and clozapine increase neural activity in the rat prefrontal cortex. Neurosci. Lett. 298(3):2001;217-221.
22. Lewis R. Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms. Can. J. Psychiatry. 43(6):1998;596-604.
23. McCulloch J., Savaki H.E., Sokoloff L. Distribution of the effects of haloperidol on energy metabolism in the rat brain. Brain Res. 243:1982;81-90.
24. McIntosh A.R., Gonzalez L.F. Large-scale functional connectivity in associative learning: interrelations of the rat auditory, visual, and limbic systems. J. Neurophysiol. 80(6):1998;3148-3162.
25. Meibach R.C., Glick S.D., Ross D.A., Cox R.D., Maayani S. Intraperitoneal administration and other modifications of the 2-deoxy-D-glucose technique. Brain Res. 195:1980;167-176.
26. I values. J. Pharmacol. Exp. Ther. 251:1989;238-246.
27. Miller C.H., Mohr F., Umbricht D., Woerner M., Fleischhacker W.W., Lieberman J.A. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J. Clin. Psychiatry. 59:1998;69-75.
28. Miyamoto S., Leipzig J.N., Lieberman J.A., Duncan G.E. Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice. Neuropsychopharmacology. 22(4):2000;400-412.
29. 1 receptor stimulation in 6-OHDA lesioned rats: effect of sensitization (priming) with a dopaminergic agonist. Synapse. 13:1993;264-269.
30. Nakahara T., Kuroki T., Hashimoto K., Hondo H., Tsutsumi T., Motomura K., Ueki H., Hirano M., Uchimura H. Effect of atypical antipsychotics on phencyclidine-induced expression of arc in rat brain. NeuroReport. 11(3):2000;551-555.
31. Nilsson M., Waters S., Waters N., Carlsson A., Carlsson M.L. A behavioural pattern analysis of hypoglutamatergic mice - effects of four different antipsychotic agents. J. Neural Transm. 108(10):2001;1181-1196.
32. Ori C., Dam M., Pizzolato G., Battistin L., Giron G. Effects of isoflurane anesthesia on local cerebral glucose utilization in the rat. Anesthesiology. 65(2):1986;152-156.
33. Paxinos G., Watson C. The Rat Brain in Sterotaxic Coordinates. Second Edition:1986;Academic Press, Orlando.
34. Pazos A., Probst A., Palacios J.M. Serotonin receptors in the human brain - IV. Autoradiographic mapping of serotonin-2 receptors. Neurosci. 21(1):1987;123-139.
35. Pizzolato G., Soncrant T.T., Larson D.M., Rapoport S.I. Reduced metabolic response of the rat brain to haloperidol after chronic treatment. Brain Res. 337:1985;1-9.
36. Potkin S.G., Buschsbaum M.S., Jin Y., Tang C., Telford J., Friedman G., Lottenberg S., Najafi A., Gulasekaram B., Costa J. Clozapine effects on glucose metabolic rate in striatum and frontal cortex. J. Clin. Psychiatry. 55(Suppl. B):1994;63-66.
37. Rasmussen J.G.C. Drug treatments for schizophrenia - past, present, and future. Int. J. Psychiatry Clin. Pract. 1(4):1997;227-230.
38. 3H]-2-Deoxyglucose uptake study in mutant dystonic hamsters: abnormalities in discrete brain regions of the motor system. Mov. Disord. 13(4):1998;718-725.
39. 2 receptors, and schizophrenia. Lidow M.S. Neurotransmitter Receptors in Actions of Antipsychotic Medications. Pharmacology and Toxicology. 2000;43-63 CRC Press, Boca Raton, FL.
40. Sharp F.R., Kilduff T.S., Bzorgchami S., Heller H.C., Ryan A.F. The relationship of local cerebral glucose utilization to optical density ratios. Brain Res. 263:1983;97-103.
41. Sheitman B.B., Kinon B.J., Ridgway B.A., Lieberman J.A. Pharmacological treatments of schizophrenia. Nathan P.E., Gorman J.M. A Guide to Treatments that Work. 1988;167-189 Oxford Univ. Press, New York.
42. Surmann A., Havemann-Reinecke U. Injection of apomorphine - a test to predict individual different dopaminergic sensitivity? J. Neural Transm., Suppl. 45:1995;143-155.
43. Van-Hartesveldt B., Lindquist D. Behavioral effects of basal gangliar lesions in neonatal rats. Dev. Psychobiol. 11(2):1978;151-160.
44. Watson P.J. Non-motor functions of the cerebellum. Psychol. Bull. 85(5):1978;944-967.
45. Wolkin A., Sanfilipo M., Duncan E., Angrist B., Wolf A.P., Cooper T.B., Brodie J.D., Laska E., Rotrosen J.P. Blunted change in cerebral glucose utilization after haloperidol treatment in schizophrenic patients with prominent negative symptoms. Am. J. Psychiatry. 153(3):1996;346-354.
46. Wooten G.F., Collins R.C. Metabolic effects of unilateral lesion of the substantia nigra. J. Neurosci. 1(3):1981;285-291.